Clinical trials: Diabetes Type 1
- Condition Diabetes Type 1
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy, Type 1 Diabetes
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when the immune system does not identify part of the body as belonging to it.
- Trial name
- NCT00896077
- Testing
- Lisofylline
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DiaKine Therapeutics, Inc.
Healthy Volunteer, Type 2 Diabetes
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes…
- Trial name
- NCT02164266
- Testing
- RO6799477
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device
Continuous monitoring of the skin tissue glucose concentration on two different study days using glucose sensors that work on the principle of impedance spectroscopy, with systematic alteration of the blood glucose concentration…
- Trial name
- NCT01060917
- Testing
- Non-invasive CGMS (continuous glucose monitoring system), Hyperglycemic and hypoglycemic glucose clamp, Non-invasive CGMS (GlucoDay)
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems
The purpose of the study is to evaluate the safety and effectiveness of the Abbott Sensor Based Glucose Monitoring System Personal (System-P) and Abbott Sensor Based Glucose Monitoring System Professional (System-Pro) when used…
- Trial name
- NCT02283411
- Testing
- Abbott Sensor Based Glucose Monitoring System
- Where
- 6 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Abbott Diabetes Care
Healthy, Type 1 Diabetes Mellitus
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT06280703
- Testing
- LY3938577, Insulin Degludec, Insulin Lispro
- Where
- Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Impairment, Type 2 Diabetes Mellitus
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with…
- Trial name
- NCT01948986
- Testing
- Ertugliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
This study will be conducted in a Clinical Research Center (CRC) setting and recruiting type 1 diabetes that are currently using an insulin pump.
- Trial name
- NCT01919385
- Testing
- Predictive Low Glucose Minimizer
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
T1D, Type 1 Diabetes (T1D)
Evaluation of a Biopsychosocial System
The goal of this observational study is to evaluate the feasibility of a biopsychosocial sensing system integrated into the Adhera Caring Digital Program® for caregivers of children with type 1 diabetes (T1D).
- Conditions
- T1D, Type 1 Diabetes (T1D), Type 1 Diabetes
- Trial name
- NCT07440108
- Testing
- Use of Biopsychosocial Sensing System
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
- Trial name
- NCT00071448
- Testing
- insulin human, insulin lispro, insulin aspart
- Where
- 76 sites in United States
- Volunteers
- 378 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A SAD Study of ZT002 Injection in Healthy Participants
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.
- Trial name
- NCT06423872
- Testing
- ZT002
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Healthy Volunteers, Type 1 Diabetes
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
First in human study to understand the potential side effects of MTX-101, how long MTX-101 lasts in the human body, and how MTX-101 affects specific human immune cells.
- Trial name
- NCT06324604
- Testing
- MTX-101
- Where
- 3 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Mozart Therapeutics Australia Pty Ltd
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Type 2 Diabetes Mellitus
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
- Trial name
- NCT06492655
- Testing
- CKD-383(Fed), CKD-383(Fasted)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
In this study the effect of ipragliflozin on glucose homeostasis in healthy subjects and T2DM subjects, and the effect of exposure of ipragliflozin on urinary glucose excretion and plasma glucose in T2DM subjects will be…
- Trial name
- NCT01611363
- Testing
- ASP1941
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Type 2 Diabetes Mellitus
Japanese Phase 1 Multiple Ascending Dose Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01515202
- Testing
- BMS-823778
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 1
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B.
- Trial name
- SINT1A (NCT04769037)
- Testing
- B. infantis
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 1,149 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München